What's new in the management of cutaneous T-cell lymphoma?

V. McFarlane; P. S. Friedman; Tim M. Illidge

doi:10.1016/j.clon.2004.11.010

What's new in the management of cutaneous T-cell lymphoma?

V. McFarlane, P. S. Friedman, Tim M. Illidge

Research output: Contribution to journal › Article › peer-review

Abstract

The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines. © 2005 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	174-184
Number of pages	10
Journal	Clin Oncol (R Coll Radiol)
Volume	17
Issue number	3
DOIs	https://doi.org/10.1016/j.clon.2004.11.010
Publication status	Published - May 2005

Keywords

Cutaneous lymphoma
Electron beam therapy
Novel therapies
Radiotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2004.11.010

Cite this

@article{6b01e3a3d9e2470f92eae80d7af76653,

title = "What's new in the management of cutaneous T-cell lymphoma?",

abstract = "The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines. {\textcopyright} 2005 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.",

keywords = "Cutaneous lymphoma, Electron beam therapy, Novel therapies, Radiotherapy",

author = "V. McFarlane and Friedman, {P. S.} and Illidge, {Tim M.}",

year = "2005",

month = may,

doi = "10.1016/j.clon.2004.11.010",

language = "English",

volume = "17",

pages = "174--184",

journal = "Clin Oncol (R Coll Radiol)",

issn = "0936-6555",